Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Standard of Care in Second-Line Treatment for Relapsed/Refractory Large B-Cell Lymphoma in Spain.
Alejandro Martin Martin Garcia-SanchoMaría PresaCarlos PardoVictoria Martín-EscuderoItziar OyagüezValentín Ortiz-MaldonadoPublished in: Cancers (2024)
Axi-cel is a potentially cost-effective alternative to HDT+ASCT for the treatment of R/R DLBCL in Spain.